This is a working overview of GIP receptor, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2025-11-15. Anything still debated is marked as such rather than presented as settled.
Clinical development proceeded through large phase 3 programmes in type 2 diabetes and in obesity or overweight with at least one weight-related comorbidity. Regulatory approvals followed in several jurisdictions for both indications. Weekly subcutaneous dosing reflects an elimination half-life of roughly five days. Open questions include the durability of metabolic effects after treatment stops, long-term cardiovascular and hepatic outcomes beyond completed trials, and whether the dual mechanism confers benefits independent of total receptor occupancy. Published literature continues to expand on these points. Substantial uncertainty remains about interindividual variability in response.
Tirzepatide is a synthetic linear peptide of 39 amino acids that acts as a dual agonist at the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. Its sequence derives from native GIP but incorporates non-natural residues and a C20 fatty diacid moiety linked to a lysine side chain. The lipophilic chain promotes albumin binding, which slows renal clearance and extends circulation time. The unmodified peptide has a molecular formula of C225H348N48O68 and a molecular mass near 4,813 daltons.
Identity and purity are assessed by reversed-phase high-performance liquid chromatography, with mass confirmation by electrospray ionisation mass spectrometry. Peptide mapping after enzymatic digestion verifies the primary sequence. Size-exclusion chromatography quantifies aggregates, while circular dichroism provides a secondary-structure fingerprint. Bioanalytical quantification in plasma uses immunoassay or LC-MS/MS. Reported purity for research-grade lots is commonly 95 percent or higher, and residual water content is checked by Karl Fischer titration.
As a peptide, tirzepatide is handled as a lyophilised solid in research settings and as a preserved solution in finished products. Aqueous solubility is pH dependent and reaches a minimum near the isoelectric point, which lies close to pH 5.4. Stock solutions are typically prepared in neutral or slightly basic buffer to limit precipitation. The solid is hygroscopic and should be equilibrated to room temperature before opening so that condensation does not form on the powder surface.
Recommended storage for reference material is a freezer at approximately -20 degrees Celsius, protected from light and moisture. Commercial injectable presentations are stored refrigerated between 2 and 8 degrees Celsius and must not be frozen. Product labelling generally permits a limited period at controlled room temperature once dispensed, with the exact window depending on the presentation. Repeated temperature cycling is avoided because it can promote aggregation or deamidation of the peptide chain.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C225H348N48O68 | Unmodified peptide backbone |
| Molecular mass | approx. 4,813 Da | 39-residue linear chain |
| Receptor targets | GIP and GLP-1 | Dual agonist activity |
| Route | Subcutaneous injection | Weekly administration interval |
| Elimination half-life | approx. 5 days | Supports weekly dosing schedule |
An extended fatty diacid moiety promotes binding to serum albumin, which slows renal clearance and extends the circulating half-life to roughly five days. That property supports once-weekly administration and largely explains the dosing interval described in clinical reports. Published data come mainly from large randomised programmes that evaluated glycaemic control and body weight over periods of many months. Long-term outcomes beyond those trial windows, including what happens after treatment stops, remain an active area of investigation.
Tirzepatide is a synthetic peptide built from thirty-nine amino acids. Its sequence is derived from native glucose-dependent insulinotropic polypeptide, or GIP, with several non-natural residues and a fatty diacid side chain attached through a linker. The molecule behaves as a dual agonist at two incretin receptors, GIP and GLP-1, instead of targeting a single receptor. This dual engagement separates it from earlier single-receptor incretin compounds and underpins most of its reported pharmacological activity.
At the receptor level, the compound binds both GIP and GLP-1 receptors and triggers downstream signalling that raises cyclic AMP in target cells. GLP-1 receptor activation is associated with glucose-dependent insulin release, slower gastric emptying, and reduced appetite signalling. GIP receptor activation contributes effects that are less completely characterised, and how much each receptor adds to the overall clinical response is still an open question. The two pathways appear to interact in a complementary rather than a purely additive way.
Like most synthetic peptides of this size, the material is commonly supplied as a lyophilised powder that appears white to off-white. It dissolves in aqueous buffers and in mixtures of water with a small proportion of organic solvent, though the fatty acid portion reduces solubility in pure water relative to short peptides. Hygroscopic behaviour is reported for many peptide powders, so weighing is usually performed quickly and under controlled humidity. Working solutions are typically prepared fresh and kept cold.
Long-term storage of lyophilised peptide powder is generally at minus twenty degrees Celsius or colder, with desiccant and protection from light. Short-term storage at two to eight degrees Celsius is common during active use. In solution, stability depends strongly on pH, concentration, and the presence of preservatives, and hydrolysis or aggregation can develop over weeks. Published stability data specific to this molecule are limited, so recommended conditions for research material are usually extrapolated from general peptide handling practice rather than from a dedicated study.
Bulk peptide material is normally characterised by reversed-phase high-performance liquid chromatography, which separates the target sequence from truncation products and other closely related impurities. Ultraviolet detection near 214 nanometres is common because the peptide backbone absorbs in that region. Mass spectrometry, usually electrospray ionisation coupled to a mass analyser, is used to confirm the molecular mass. Because the molecule carries a lipophilic side chain, gradient methods often need a relatively high organic modifier fraction to elute it within a practical retention window.
In clinical research, tirzepatide has been studied in randomized controlled trials for glycemic control and body weight reduction. These trials typically measure changes in hemoglobin A1c and body weight over periods of several months. The drug is administered by subcutaneous injection, and its pharmacokinetic profile supports once-weekly dosing. Post-marketing surveillance continues to evaluate long-term outcomes and rare adverse events.
Tirzepatide is a synthetic peptide that acts as a dual agonist at the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. The molecule contains 39 amino acids and features a C20 fatty diacid moiety attached via a linker, which promotes albumin binding and extends its circulating half-life. Its sequence incorporates non-natural amino acids and modifications that reduce susceptibility to degradation by dipeptidyl peptidase-4. This dual receptor activity distinguishes it from selective GLP-1 receptor agonists.
== Diabetes == Increased IMTG was once thought responsible for increased insulin resistance. However, the discovery that athletes as well as obese individuals have high IMTG levels confounded these findings. Instead, IMTG metabolites, such as diacylglycerol and ceramide are responsible for the insulin resistance. Studies demonstrating the effects of IMTGs show that the mechanism involves the activation of the protein kinase C theta, which promotes the phosphorylation of IRS-1, thereby inhibiting the insulin signaling cascade.
ISBN 0-89966-613-2 OCLC 68043161 Cooke, James J. The All-Americans at War: The 82nd Division in the Great War, 1917–1918. Westport, Conn: Praeger, 1999. ISBN 0-275-95740-3 OCLC 39210048 Cooksey, Jon. Crossing the Waal: The US 82nd Airborne Division at Nijmegen. Barnsley: Pen and Sword Military, 2005. ISBN 1-84415-228-6 OCLC 57200754 Covington, Henry L. A Fighting Heart, An Unofficial Story of the 82nd Airborne Division. Fayetteville, NC: T. Davis, 1949. OCLC 4139070 Dawson, Buck. Saga of the All American. Atlanta: Albert Love Enterprises, 1946. OCLC 3595988 Francois, Dominique. 82nd Airborne Division 1917–2005. Bayeux: Heimdal, 2006. ISBN 2-84048-215-0 OCLC 64967339 Gavin, James M. On to Berlin: Battles of an Airborne Commander, 1943–1946. New York: Viking Press, 1978. ISBN 0-670-52517-0 OCLC 3204743 Grey, Stephen. Into the Viper's Nest: The First Pivotal Battle of the Afghan War. Minneapolis: Zenith Press, 2010. ISBN 0-7603-3897-3 OCLC 548583278 Heilman, William H. A Pilot's Tale: Flying Helicopters in Vietnam. Hooks, Tex.?: William H. Heilman, 2008. ISBN 1-4357-1185-8 OCLC 671642623 Hoyt, Edwin Palmer. The Invasion Before Normandy: The Secret Battle of Slapton Sands. Lanham, MD: Scarborough House, 1999. ISBN 0-8128-8562-7 OCLC 41712914 Imai, Kesaharu. Grenada : 25 October to 2 November 1983. Tokyo: World Photo Press, 1984. OCLC 16348601 Langdon, Allen. Ready: The History of the 505th Parachute Infantry Regiment, 82nd Airborne Division, World War II. [Fort Bragg, N.C.]: The Division, 1986. OCLC 16221387 Lebenson, Leonard.
Thus, it may serve to sequester potentially toxic metal ions, protecting the rest of the cell. This hypothesis is supported by the fact that the loss of neuromelanin, observed in Parkinson's disease, is accompanied by an increase in iron levels in the brain.
be a South Sudanese citizen; be at least twenty-one years of age; be of sound mind; be literate; and not have been convicted during the last seven years of an offence involving honesty or moral turpitude. Members of the National Legislature and the Council of Ministers are eligible for membership of state legislatures or state councils of ministers. A member of the National Legislative Assembly cannot also be a member of the Council of States (and vice versa). The term of the National Legislature shall be four years from July 9, 2011. The Constitution is a transitional Constitution and the terms relating to future general elections are not contained in it. However, there are provisions included for by-elections should vacancies arise during the first four-year period.
Two abnormal proteins define the pathology of Alzheimer's disease: amyloid beta protein (Aβ) in amyloid plaques and tau protein in neurofibrillary tangles. These proteins share two features that promote their ability to cause disease: They both become abnormal by misfolding, that is, by assuming a shape that is rich in beta sheets; and they proliferate in the brain by the prion-like mechanism of seeded protein aggregation. The presence of these abnormal proteins in Alzheimer's disease has spawned two hypotheses of the proteopathic origin of the disease: The amyloid (or Aβ) hypothesis, and the tau hypothesis. The amyloid hypothesis, also known as the "amyloid cascade hypothesis" or "Aβ cascade hypothesis", holds that the accumulation of misfolded Aβ in the brain is the fundamental cause of Alzheimer's disease. In the amyloid cascade, the buildup of abnormal Aβ leads to tauopathy and eventually the complex degenerative changes of advanced Alzheimer's disease. Abnormal Aβ is thought to damage the brain by directly interacting with cells, as well as indirectly, for example by causing oxidative stress and neuroinflammation. The amyloid hypothesis is supported by evidence from genetics and biomarkers. All autosomal dominant genetic causes of Alzheimer's disease affect either the amyloid precursor protein (APP) on chromosome 21 or the enzymes that generate Aβ, known as presenilin 1 and presenilin 2.
Sources: en.wikipedia.org
== Consistency == Various studies on a particular topic often do not address the same outcomes, making it difficult to draw clinically useful conclusions when a group of studies is looked at as a whole. The Core Outcomes in Women's Health (CROWN) Initiative is one effort to standardize outcomes.
== Analogs == Growth-hormone-releasing hormone is the lead compound for a number of structural and functional analogs, such as Pro-Pro-hGHRH(1-44)-Gly-Gly-Cys, CJC-1293, and CJC-1295. Many GHRH analogs remain primarily research chemicals, although some have specific applications. Sermorelin, a functional peptide fragment of GHRH, has been used in the diagnosis of deficiencies in growth hormone secretion. Tesamorelin, under the trade name Egrifta, received U.S. Food and Drug Administration approval in 2010 for the treatment of lipodystrophy in HIV patients under highly active antiretroviral therapy, and, in 2011, was investigated for effects on certain cognitive tests in the elderly. As a category, the use of GHRH analogs by professional athletes may be prohibited by restrictions on doping in sport because they act as growth hormone secretagogues.
Ever since the appearance and spread of rival organizations during the late 80s to the early 90s (both in Rio and other states), CV has waged major turf wars against other cartels and street gangs. In recent years it has been involved in a series of prison riots, massacres and territorial conflicts thorough the entire country, which resulted in dozens (or sometimes even hundreds) of casualties, mostly involving police militias (which have grown considerably in the past decade) and rival gangs such as ADA, GDE and TCP. After negotiations for an "alliance" with São Paulo–based PCC broke down in 2016 (mainly due to disputes between shared drugs and arms trafficking routes in Paraguay, Bolivia and Colombia), a series of retaliations (which included mass shootings, executions and invasions of rival favelas) broke out between both groups and their allies, which have resulted in severe casualties, including not only gang members but also many innocent civilians and security officials who have been caught in the crossfire. However, despite years of violent conflicts with the Brazilian police and other criminal organizations, as well as deterrent efforts such as the Police Pacifying Unit (UPP) and the occupation of several favelas, the CV maintains significant power and governance in many of Rio de Janeiro's favelas, and, like many other organizations, has increasingly been portrayed as a "cultural icon" in some genres of Brazilian music (such as in the Proibidão, Ostentação and Automotivo sub-genres of Brazilian funk, Trap and Hip-Hop).
The physics of FTICR is similar to that of a cyclotron at least in the first approximation. In the simplest idealized form, the relationship between the cyclotron frequency and the mass-to-charge ratio is given by
=== General References === ASTM F1416 Standard Guide for Selection of Time-Temperature Indicators Yam, K. L., "Encyclopedia of Packaging Technology", John Wiley & Sons, 2009, ISBN 978-0-470-08704-6 Taoukis, P. and T.P. Labuza. 2003. Time temperature indicators. In: Novel Food Packaging Techniques. R. Ahvenainen (ed.). Woodhead Publ., Cambridge, UK.
Sources: en.wikipedia.org
It is a dual GIP and GLP-1 receptor agonist, frequently grouped with incretin-based peptide therapeutics. It is a peptide rather than a small molecule and is given by subcutaneous injection.
Selective agents engage only the GLP-1 receptor, whereas tirzepatide activates GIP and GLP-1 receptors simultaneously. This difference in receptor coverage is the principal pharmacological distinction emphasised in comparative reviews.
Downstream signalling is partly characterised, but the quantitative contribution of GIP versus GLP-1 receptor activation to metabolic outcomes is not settled. Review articles commonly flag this as an unresolved question rather than a settled finding.
Solid material is normally kept frozen at about -20 degrees Celsius, desiccated and protected from light. Solutions are held cold and used within a defined window because degradation products accumulate over time.